Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 3
2023 4
2024 8
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
La prise en charge des cancers médullaires de la thyroïde en 2024.
Lasolle H, Borson-Chazot F, Gauduchon T, Haissaguerre M, Illouz F, Lifante JC, Lussey-Lepoutre C, Prunier D, Sajous C, Varnier R, Hadoux J. Lasolle H, et al. Among authors: varnier r. Bull Cancer. 2024 Oct;111(10S1):10S53-10S63. doi: 10.1016/S0007-4551(24)00408-9. Bull Cancer. 2024. PMID: 39505437 Review. French.
[The words to say it].
Colin C, Varnier R. Colin C, et al. Among authors: varnier r. Bull Cancer. 2024 Jun;111(6):552-553. doi: 10.1016/j.bulcan.2024.03.008. Epub 2024 May 8. Bull Cancer. 2024. PMID: 38724336 French. No abstract available.
Selpercatinib in the treatment of thyroid cancer.
Gauduchon T, Varnier R, Cassier PA. Gauduchon T, et al. Among authors: varnier r. Future Oncol. 2025 Aug;21(20):2585-2592. doi: 10.1080/14796694.2025.2531575. Epub 2025 Jul 10. Future Oncol. 2025. PMID: 40638871 Review.
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.
Varnier R, Pérol D, Jacot W, Mailliez A, Diéras V, Dalenc F, Gonçalves A, Levy C, Arnedos M, Frenel JS, Bailleux C, Massard V, Brain E, Sauterey B, Savoye AM, Bosquet L, Thery JC, Petit T, Bachelot T, Grinda T, Ray-Coquard I. Varnier R, et al. ESMO Open. 2025 Oct;10(10):105803. doi: 10.1016/j.esmoop.2025.105803. Epub 2025 Sep 17. ESMO Open. 2025. PMID: 40967066 Free PMC article.
Clinical and biological factors associated with response to immune checkpoint inhibitors in advanced sarcomas: IMPRESARC, a French retrospective multicenter cohort study.
Fazel M, Varnier R, Vanacker H, Penel N, Watson S, Verret B, Valentin T, Bompas E, Waissi W, Meurgey A, Ducimetière F, Blay JY, Dufresne A, Brahmi M. Fazel M, et al. Among authors: varnier r. Cancer. 2025 Sep 15;131(18):e70052. doi: 10.1002/cncr.70052. Cancer. 2025. PMID: 40911493 Free PMC article.
[Last year of residency for oncologists: Overview and perspectives].
Laune Q, Varnier R, Rousseau A, Larnaudie A, Ghannam Y, Huguet F, Delaye M. Laune Q, et al. Among authors: varnier r. Bull Cancer. 2024 Feb;111(2):142-152. doi: 10.1016/j.bulcan.2023.08.005. Epub 2023 Oct 14. Bull Cancer. 2024. PMID: 37845094 French.
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B. Varnier R, et al. Cancer Chemother Pharmacol. 2023 May;91(5):361-373. doi: 10.1007/s00280-023-04508-9. Epub 2023 Feb 25. Cancer Chemother Pharmacol. 2023. PMID: 36840749 Clinical Trial.
19 results